Every story in this section, newest first — page 170 of 373.
EUDA Health Holdings (NASDAQ:EUDA) announced the expansion of its proprietary Helixé product portfolio with the commercial launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask.
Agios Pharmaceuticals (NASDAQ:AGIO) has acquired an exclusive global license for Oscotec's cevidoplenib, an experimental oral treatment for a rare blood disorder, betting the asset can capture up to $1 billion in peak U.S. sales despite recently missing the main goal of a mid-stage trial.
Moderna (NASDAQ:MRNA) has expanded its strategic collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo ebolavirus strain, an aggressive cause of Ebola virus disease for which there are currently no approved or licensed immunizations.
Li Auto (NASDAQ:LI) announced Monday that it delivered 33,350 vehicles in May 2026, securing steady volume as the premium automaker kickstarts a fresh product refresh cycle across its smart electric vehicle lineup.
Oil prices climbed sharply in early Asian trading on Monday as a significant escalation of military activity across the Middle East intensified fears of a prolonged disruption to global energy supplies, overshadowing weak economic indicators from China.
NIO (NYSE:NIO) reported total deliveries of 37,705 vehicles for May 2026, representing a 62.3% increase compared to the same period last year.
XPENG (NYSE:XPEV) announced total vehicle deliveries of 32,158 units for May 2026, continuing a steady upward path in the highly competitive smart electric vehicle market.
Camurus (NASDAQ:CAMX) announced Monday that Eli Lilly (NYSE:LLY) has formally exercised its option to integrate amylin receptor agonists into the companies' existing cardiometabolic collaboration and license agreement.
Lucid Group (NASDAQ:LCID) announced that Silvio Napoli has officially assumed the role of Chief Executive Officer (CEO), effective immediately.
Uber Technologies (NYSE:UBER) and Israel-based autonomous vehicle technology developer Autobrains announced on Monday a joint initiative to launch a commercial robotaxi program in Munich, marking an expansive push to scale autonomous ride-hailing infrastructure across Europe.
Dynagas LNG Partners (NYSE:DLNG) reported a 27.9% increase in first-quarter net income, driven by robust vessel operations and stable fixed-term employment across its maritime liquefied natural gas shipping assets.
The Bank of Nova Scotia (Scotiabank) (NYSE:BNS) has signed a definitive agreement to acquire Maple Financial Holdings, the parent company of MapleMark Bank, a U.S. commercial bank based in Dallas, Texas. Financial terms of the transaction were not immediately disclosed.
Elmet Group (NASDAQ:ELMT) reported a 20.7% increase in first-quarter revenue, propelled by expanding volumes in its core aerospace, defense, and government end markets.
Ondas (NASDAQ:ONDS) secured more than $30 million in new contracts during May 2026, pushing its total second-quarter orders to date beyond $110 million.
HomesToLife (NASDAQ:HTLM) reported a 36% increase in first-quarter net profit, driven by accelerating export demand and expanding gross margins that counterbalanced an uptick in operating costs and foreign currency headwinds.
Tempus AI (NASDAQ:TEM) announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform.
Johnson & Johnson (NYSE:JNJ) reported positive late-stage clinical data for its blood cancer therapy Tecvayli (teclistamab-cqyv), demonstrating significant improvements in survival metrics for patients with relapsed or refractory multiple myeloma.
Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.
Best Buy (NYSE:BBY) announced that its Board of Directors has authorized the payment of a regular quarterly cash dividend of $0.96 per common share, maintaining the electronics retailer's commitment to its ongoing capital return program.
CoStar Group (NASDAQ:CSGP) has entered into a definitive agreement to acquire Zonda, a prominent provider of new home construction data, homebuilder software, and residential marketplaces, for $800 million in cash.
Pfizer (NYSE:PFE) announced unprecedented seven-year follow-up results from its Phase 3 CROWN trial, revealing that its oncology drug Lorbrena significantly extended progression-free survival in patients with a specific, aggressive form of lung cancer.
AbbVie (NYSE:ABBV) has secured authorization from the European Commission for an expanded label of its oncology drug VENCLYXTO (venetoclax) to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).
Lowe’s Companies (NYSE:LOW) authorized a 4% increase to its quarterly cash dividend, extending a multi-decade track record of annual payout increases and signaling confidence in its steady cash generation capabilities.
Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.
